Eight-plex iTRAQ analysis of variant metastatic human prostate cancer cells identifies candidate biomarkers of progression: An exploratory study

Prostate

Volumn 70, Issue 12, 2010, Pages 1313-1332

  Glen, Adam ^a   Evans, Caroline A ^a,b   Gan, Chee S ^b,f   Cross, Simon S ^b   Hamdy, Freddie C ^c   Gibbins, Jonathan ^d,e   Lippitt, Jenny ^a   Eaton, Colby L ^a   Noirel, Josselin ^b   Wright, Phillip C ^b   Rehman, Ishtiaq ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF READING   (United Kingdom)

^e KING SAUD UNIVERSITY   (Saudi Arabia)

^f AGILENT TECHNOLOGIES   (Singapore)

Author keywords

LNCaP; Methylation; PC 3; Proteomic; Vimentin

Indexed keywords

ACTININ; ANNEXIN; CALNEXIN; CALRETICULIN; CATALASE; COFILIN; CREATINE KINASE; CYTOCHROME C; CYTOKERATIN; DNA; ELONGATION FACTOR; FILAMIN; FK 506 BINDING PROTEIN; GLUCOSIDASE; HEAT SHOCK PROTEIN; HEPATOMA DERIVED GROWTH FACTOR; HISTONE; MESSENGER RNA; MYOSIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PLECTIN; PROTEIN DISULFIDE ISOMERASE; PROTEOME; PYRUVATE KINASE; RAS PROTEIN; THIOREDOXIN; TRANSKETOLASE; TUMOR MARKER; UNINDEXED DRUG; VIMENTIN;

ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER GROWTH; CELL STRAIN LNCAP; CONTROLLED STUDY; DNA METHYLATION; GENE EXPRESSION; GENE SEQUENCE; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; ISOBARIC TAGS FOR RELATIVE AND ABSOLUTE QUANTITATION ANALYSIS; MALE; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RANK SUM TEST; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; DISEASE PROGRESSION; GENETIC VARIATION; HEAT-SHOCK PROTEINS; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; MALE; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TRANSKETOLASE; TUMOR CELLS, CULTURED;

EID: 77956388479     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21167     Document Type: Article

References (64)

1. Damber JE, Aus G. Prostate cancer. Lancet 2008;371(9625):1710-1721.
2. Gronberg H. Prostate cancer epidemiology. Lancet 2003;361(9360):859-864.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-249.
4. Coleman RE. Clinical features of metastatic bone diseaseand risk of skeletal morbidity. Clin Cancer Res 2006;12(20 Pt 2):6243s-6249s.
5. Joniau S, Van Poppel H. Localized prostate cancer: Can we better define who is at risk of unfavourable outcome? BJU Int 2008;101(Suppl 2):5-10.
6. Klotz L. Active surveillance for prostate cancer: For whom? J Clin Oncol 2005;23(32):8165-8169.
7. LaSpina M, Haas GP. Update on the diagnosis and management of prostate cancer. Can J Urol 2008;15(Suppl 1):3-13;discussion 13.
8. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring. Nat Rev Cancer 2008;8(4):268-278. (Pubitemid 351430866)
9. van Gils MP, Stenman UH, Schalken JA, Schroder FH, Luider TM, Lilja H, Bjartell A, Hamdy FC, Pettersson KS, Bischoff R, Takalo H, Nilsson O, Mulders PF, Bangma CH. Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project. Eur Urol 2005;48(6):1031-1041. (Pubitemid 41641661)
10. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004;350(22):2239-2246.
11. Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P, Montorsi F, Stief CG, Schroder F. Insignificant prostate cancer and active surveillance: From definition to clinical implications. Eur Urol 2009;55(6):1321-1330.
12. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ, Fidler IJ. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 1996;2(9):1627-1636. (Pubitemid 126447459)
13. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK, Sandberg AA. The LNCaP cell line - A new model for studies on human prostatic carcinoma. Prog Clin Biol Res 1980;37:115-132.
14. Kaighn ME, Lechner JF, Narayan KS, Jones LW. Prostate carcinoma: Tissue culture cell lines. Natl Cancer Inst Monogr 1978; (49):17-21. (Pubitemid 9152618)
15. Hellstrom M, Lexander H, Franzen B, Egevad L. Proteomics in prostate cancer research. Anal Quant Cytol Histol 2007;29(1):32-40.
16. Masters JR. Clinical applications of expression profiling and proteomics in prostate cancer. Anticancer Res 2007;27(3A):1273-1276. (Pubitemid 46807272)
17. Matharoo-Ball B, Ball G, Rees R. Clinical proteomics: Discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches - A prostate cancer perspective. Vaccine 2007;25(Suppl 2):B110-B121.
18. Schiffer E. Biomarkers for prostate cancer. World J Urol 2007;25(6):557-562.
19. Tyson DR, Ornstein DK. Proteomics of cancer of hormone-dependent tissues. Adv Exp Med Biol 2008;630:133-147.
20. Byrne JC, Downes MR, O'Donoghue N, O'Keane C, O'Neill A, Fan Y, Fitzpatrick JM, Dunn M, Watson RW. 2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer. J Proteome Res 2009;8(2):942-957.
21. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005;8(5):393-406.
22. Wei J, Xu G, Wu M, Zhang Y, Li Q, Liu P, Zhu T, Song A, Zhao L, Han Z, Chen G, Wang S, Meng L, Zhou J, Lu Y, Ma D. Overexpression of vimentin contributes to prostate cancer invasion and metastasis via src regulation. Anticancer Res 2008;28(1A):327-334.
23. Malik G, Rojahn E, Ward MD, Gretzer MB, Partin AW, Semmes OJ, Veltri RW. SELDI protein profiling of dunning R-3327 derived cell lines: Identification of molecular markers of prostate cancer progression. Prostate 2007;67(14):1565- 1575.
24. Li J, White N, Zhang Z, Rosenzweig J, Mangold LA, Partin AW, Chan DW. Detection of prostate cancer using serum proteomics pattern in a histologically confirmed population. J Urol 2004;171(5):1782-1787.
25. Liu AY, Zhang H, Sorensen CM, Diamond DL. Analysis of prostate cancer by proteomics using tissue specimens. J Urol 2005;173(1):73-78.
26. Aggarwal K, Choe LH, Lee KH. Shotgun proteomics using the iTRAQ isobaric tags. Brief Funct Genomic Proteomic 2006;5(2):112-120.
27. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S, Purkayastha S, Juhasz P, Martin S, Bartlet-Jones M, He F, Jacobson A, Pappin DJ. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 2004;3(12):1154-1169.
28. Zieske LR. A perspective on the use of iTRAQ reagent technology for protein complex and profiling studies. J Exp Bot 2006;57(7):1501-1508.
29. Garbis SD, Tyritzis SI, Roumeliotis T, Zerefos P, Giannopoulou EG, Vlahou A, Kossida S, Diaz J, Vourekas S, Tamvakopoulos C, Pavlakis K, Sanoudou D, Constantinides CA. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry. J Proteome Res 2008;7(8):3146-3158.
30. Khan AP, Poisson LM, Bhat V, Fermin D, Zhao R, Kalyana-Sundaram S, Michailidis G, Nesvizhskii AI, Omenn GS, Chinnaiyan AM, Sreekumar A. Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer. Mol Cell Proteomics 2009.
31. Glen A, Gan CS, Hamdy FC, Eaton CL, Cross SS, Catto JW, Wright PC, Rehman I. iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression. J Proteome Res 2008;7(3):897-907.
32. Ow SY, Cardona T, Taton A, Magnuson A, Lindblad P, Stensjo K, Wright PC. Quantitative shotgun proteomics of enriched heterocysts from Nostoc sp. PCC 7120 using 8-plex isobaric peptide tags. J Proteome Res 2008;7(4):1615-1628.
33. Elias JE, Gygi SP. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods 2007;4(3):207-214.
34. Thomas PD, Kejariwal A, Campbell MJ, Mi H, Diemer K, Guo N, Ladunga I, Ulitsky-Lazareva B, Muruganujan A, Rabkin S, Vandergriff JA, Doremieux O. PANTHER: A browsable database of gene products organized by biological function, using curated protein family and subfamily classification. Nucleic Acids Res 2003;31(1):334-341.
35. Rehman I, Cross SS, Catto JW, Leiblich A, Mukherjee A, Azzouzi AR, Leung HY, Hamdy FC. Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer. Prostate 2005;65(4):322-330.
36. Jordan PA, Stevens JM, Hubbard GP, Barrett NE, Sage T, Authi KS, Gibbins JM. A role for the thiol isomerase protein ERP5 in platelet function. Blood 2005;105(4):1500-1507.
37. Rehman I, Azzouzi AR, Cross SS, Deloulme JC, Catto JW, Wylde N, Larre S, Champigneuille J, Hamdy FC. Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions. Hum Pathol 2004;35(11):1385-1391.
38. Chen WD, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L, Platzer P, Lu S, Dawson D, Willis J, Pretlow TP, Lutterbaugh J, Kasturi L, Willson JK, Rao JS, Shuber A, Markowitz SD. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 2005;97(15):1124-1132.
39. Gan CS, Chong PK, Pham TK, Wright PC. Technical, experimental, and biological variations in isobaric tags for relative and absolute quantitation (iTRAQ). J Proteome Res 2007;6(2):821-827.
40. Gumireddy K, Sun F, Klein-Szanto AJ, Gibbins JM, Gimotty PA, Saunders AJ, Schultz PG, Huang Q. In vivo selection for metastasis promoting genes in the mouse. Proc Natl Acad Sci USA 2007;104(16):6696-6701.
41. Keshamouni VG, Michailidis G, Grasso CS, Anthwal S, Strahler JR, Walker A, Arenberg DA, Reddy RC, Akulapalli S, Thannickal VJ, Standiford TJ, Andrews PC, Omenn GS. Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype. J Proteome Res 2006;5(5):1143-1154.
42. Ow SY, Salim M, Noirel J, Evans C, Rehman I, Wright PC. iTRAQ underestimation in simple and complex mixtures: The good, the bad and the ugly. J Proteome Res 2009;8(11):5347-5355.
43. Esteller M. Epigenetic gene silencing in cancer: The DNA hypermethylome. Hum Mol Genet 2007;16 (spec no. 1):R50-R59. (Pubitemid 47241842)
44. Herman JG. Epigenetic changes in cancer and preneoplasia. Cold Spring Harb Symp Quant Biol 2005;70:329-333.
45. Dezso Z, Nikolsky Y, Nikolskaya T, Miller J, Cherba D, Webb C, Bugrim A. Identifying disease-specific genes based on their topological significance in protein networks. BMC Syst Biol 2009;3:36.
46. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7(4):256-269.
47. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003;361(9361):955-964.
48. Nelson WG, DeWeese TL, DeMarzo AM. The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev 2002;21(1):3-16.
49. Li LC. Epigenetics of prostate cancer. Front Biosci 2007;12:3377-3397.
50. Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z, Irizarry RA, Morgan J, Hicks J, DeWeese TL, Isaacs WB, Bova GS, De Marzo AM, Nelson WG. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res 2008;68(21):8954-8967.
51. Sancho M, Diani E, Beato M, Jordan A. Depletion of human histone H1 variants uncovers specific roles in gene expression and cell growth. PLoS Genet 2008;4(10):e1000227.
52. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005;435(7046):1262-1266.
53. Chen N, Sun W, Deng X, Hao Y, Chen X, Xing B, Jia W, Ma J, Wei H, Zhu Y, Qian X, Jiang Y, He F. Quantitative proteome analysis of HCC cell lines with different metastatic potentials by SILAC. Proteomics 2008;8(23-24):5108-5118.
54. Teramoto R, Minagawa H, Honda M, Miyazaki K, Tabuse Y, Kamijo K, Ueda T, Kaneko S. Protein expression profile characteristic to hepatocellular carcinoma revealed by 2D-DIGE with supervised learning. Biochim Biophys Acta 2008;1784(5):764-772.
55. Cappello F, Rappa F, David S, Anzalone R, Zummo G. Immunohistochemical evaluation of PCNA, p53, HSP60, HSP10 and MUC-2 presence and expression in prostate carcinogenesis. Anticancer Res 2003;23(2B):1325-1331.
56. Lincoln DT, Ali Emadi EM, Tonissen KF, Clarke FM. The thioredoxin-thioredoxin reductase system: Over-expression in human cancer. Anticancer Res 2003;23(3B):2425-2433.
57. Prasad S, Thraves P, Dritschilo A, Kuettel M. Expression of cytokeratin-19 as a marker of neoplastic progression of human prostate epithelial cells. Prostate 1998;35(3):203-211. (Pubitemid 28211294)
58. Bedolla RG, Wang Y, Asuncion A, Chamie K, Siddiqui S, Mudryj MM, Prihoda TJ, Siddiqui J, Chinnaiyan AM, Mehra R, de Vere White RW, Ghosh PM. Nuclear versus cytoplasmic localization of filamin A in prostate cancer: Immunohistochemical correlation with metastases. Clin Cancer Res 2009;15(3):788-796.
59. Hara T, Honda K, Shitashige M, Ono M, Matsuyama H, Naito K, Hirohashi S, Yamada T. Mass spectrometry analysis of the native protein complex containing actinin-4 in prostate cancer cells. Mol Cell Proteomics 2007;6(3):479-491.
60. Jasavala R, Martinez H, Thumar J, Andaya A, Gingras AC, Eng JK, Aebersold R, Han DK, Wright ME. Identification of putative androgen receptor interaction protein modules: Cytoskeleton and endosomes modulate androgen receptor signaling in prostate cancer cells. Mol Cell Proteomics 2007;6(2):252-271.
61. Singh S, Sadacharan S, Su S, Belldegrun A, Persad S, Singh G. Overexpression of vimentin: Role in the invasive phenotype in an androgen-independent model of prostate cancer. Cancer Res 2003;63(9):2306-2311.
62. Zhang X, Fournier MV, Ware JL, Bissell MJ, Yacoub A, Zehner ZE. Inhibition of vimentin or beta1 integrin reverts morphology of prostate tumor cells grown in laminin-rich extracellular matrix gels and reduces tumor growth in vivo. Mol Cancer Ther 2009;8(3):499-508.
63. Zhao Y, Yan Q, Long X, Chen X, Wang Y. Vimentin affects the mobility and invasiveness of prostate cancer cells. Cell Biochem Funct 2008;26(5):571-577.
64. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93(14):1054-1061.